Page 94 - 《中国药房》2023年9期
P. 94

本研究也有一定的局限性:(1)纳入检测的患者样                              [J]. Biol Res Nurs,2017,19(2):170-179.
          本量有限,不能最大程度地反映群体多态性的整体影                             [10]  HAJJ  A,HALEPIAN  L,OSTA  N  E,et  al.  OPRM1
          响。下一步将增加样本量,一部分用于扩充临床试验;                                 c.118A>G polymorphism and duration of morphine treat‐
          另一部分用于开展临床试验验证,对患者进行目标基因                                 ment  associated  with  morphine  doses  and  quality-of-life
                                                                   in palliative cancer pain settings[J]. Int J Mol Sci,2017,18
          检测,按照一定的方案给药,观察患者的镇痛效果及便
                                                                  (4):669.
          秘发生情况,验证基因多态性与阿片类药物致便秘的相
                                                              [11]  GRAY K,ADHIKARY S D,JANICKI P. Pharmacogeno-
          关性。(2)癌痛患者受肿瘤类型、分期的影响较大,易导
                                                                   mics of analgesics in anesthesia practice:a current update
          致灵敏度和异质性问题,下一步研究计划纳入同一瘤
                                                                   of  literature[J].  J Anaesthesiol  Clin  Pharmacol,2018,34
          型、同一分期患者以排除影响。
                                                                  (2):155-160.
              综上所述,CYP3A5*3(058rs776746,A>G)GG、AG
                                                              [12]  SIA A T,LIM Y,LIM E C,et al. A118G single nucleotide
          型,OPRM1(047rs1799971,A>G)AA、AG 型与阿片类                     polymorphism of human mu-opioid receptor gene influences
          药物致便秘具有相关性,且上述基因型可能是患者使用                                 pain perception and patient-controlled intravenous morphine
          阿片类药物致便秘的预测因素,同时还需关注用药时间                                 consumption  after  intrathecal  morphine  for  postcesarean
          较长患者的便秘发生情况。                                             analgesia[J]. Anesthesiology,2008,109(3):520-526.
          参考文献                                                [13]  杨 菁 ,郑 斌 ,曾 晓 芳 ,等 .  亚 洲 人 群 OPRM1 基 因
          [ 1 ]  王玥,蒋葵. 阿片类药物引起的便秘病理机制及治疗进                         rs1799971 多态性和术后阿片类药物使用剂量关系的
               展[J]. 中国肿瘤临床,2021,48(16):852-857.                   Meta 分析[J]. 中国循证医学杂志,2016,16(12):1388-
          [ 2 ]  SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,  1393.
               2015[J]. CA A Cancer J Clin,2015,65(1):5-29.   [14]  SADHASIVAM S,CHIDAMBARAN V,ZHANG X, et al.
          [ 3 ]  PUSPITASARI  A,IKAWATI  Z,SWASTHIKAWATI  S,       Opioid-induced  respiratory  depression:ABCB1  transporter
               et al. High frequency of the opioid receptor µ-1 (OPRM1)   pharmacogenetics[J]. Pharmacogenomics J,2015,15(2):
               A118G  polymorphism,an  opioid  drug  therapy  related   119-126.
               gene,in  the  Indonesian  population[J].  Curr  Pharmaco-     [15]  OLESEN A E,SATO H,NIELSEN L M,et al. The genetic
               genomics Person Med,2019,17(1):64-69.               influences on oxycodone response characteristics in human
          [ 4 ]  黄仟,温泽淮. 倡议建立协调统一的药物不良反应因果                         experimental  pain[J].  Fundam  Clin  Pharmacol,2015,29
               关系评价标准[J]. 中国新药杂志,2021,30(12):1132-                (4):417-425.
               1136.                                          [16]  CREWS K R,MONTE A A,HUDDART R,et al. Clinical
          [ 5 ]  MA J,LI W Y,CHAI Q,et al. Correlation of P2RX7 gene   pharmacogenetics  implementation  consortium  guideline
               rs1718125 polymorphism with postoperative fentanyl anal-   for  CYP2D6,OPRM1,and  COMT  genotypes  and  select
               gesia in patients with lung cancer[J]. Medicine (Baltimore),  opioid  therapy[J].  Clin  Pharmacol  Ther,2021,110(4):
               2019,98(7):e14445.                                  888-896.
          [ 6 ]  PALADA V,KAUNISTO M A,KALSO E. Genetics and   [17]  PACKIASABAPATHY S,ARULDHAS B W,HORN N,
               genomics  in  postoperative  pain  and  analgesia[J].  Curr   et al. Pharmacogenomics of methadone:a narrative review
               Opin Anaesthesiol,2018,31(5):569-574.               of  the  literature[J].  Pharmacogenomics,2020,21(12):
          [ 7 ]  RUANO  G,KOST  J A.  Fundamental  considerations  for   871-887.
               genetically-guided pain management with opioids based on   [18]  NAITO  T,  TAKASHINA  Y,  YAMAMOTO  K,  et  al.
               CYP2D6 and OPRM1 polymorphisms[J]. Pain Physician,  CYP3A5*3  affects  plasma  disposition  of  noroxycodone
               2018,21(6):E611-E621.                               and dose escalation in cancer patients receiving oxycodone
          [ 8 ]  WANG  L  Z,WEI  C  N,XIAO  F,et  al.  Influences  of   [J]. J Clin Pharmacol,2011,51(11):1529-1538.
               COMT rs4680 and OPRM1 rs1799971 polymorphisms on   [19]  MURPHY L, BRANDS B, GRANT D, et al. Exploring
               chronic  postsurgical  pain,acute  pain,and  analgesic  con‐  the use of extended release opioids at shortened dosing in‐
               sumption after elective cesarean delivery[J]. Clin J Pain,  tervals  in  people  with  chronic  pain  and  high  risk  medi-
               2019,35(1):31-36.                                   cation or substance use[J]. Int J Clin Pharm,2021,43(2):
          [ 9 ]  KHALIL  H,SEREIKA  S  M,DAI  F,et  al.  OPRM1  and   404-410.
               COMT gene-gene interaction is associated with postopera‐     (收稿日期:2022-11-20  修回日期:2023-02-26)
               tive pain and opioid consumption after orthopedic trauma                           (编辑:舒安琴)





          · 1108 ·    China Pharmacy  2023 Vol. 34  No. 9                              中国药房  2023年第34卷第9期
   89   90   91   92   93   94   95   96   97   98   99